Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

被引：130

作者：

Brueckl, Wolfgang M. ^{[1
,2
]}

Ficker, Joachim H. ^{[1
,2
]}

Zeitler, Gloria ^{[2
]}

机构：

[1] Paracelsus Med Univ, Gen Hosp Nuremberg, Nuremberg Lung Canc Ctr, Dept Resp Med Allergol & Sleep Med, Prof Ernst Nathan Str 1, D-90419 Nurnberg, Germany

[2] Paracelus Med Private Univ Nuremberg, Prof Ernst Nathan Str 1, D-90119 Nurnberg, Germany

来源：

BMC CANCER | 2020年 / 20卷 / 01期

关键词：

Immunotherapy; Immune checkpoint inhibitor (ICI); PD-L1; inhibitor; NSCLC; Prognostic; Predictive; Biomarker; ENDOTHELIAL GROWTH-FACTOR; OPEN-LABEL; INFLAMMATORY BIOMARKERS; SYSTEMIC THERAPY; LYMPHOCYTE RATIO; PLEURAL EFFUSION; POOLED ANALYSIS; FACTOR VEGF; STAGE IV; DOCETAXEL;

D O I：

10.1186/s12885-020-07690-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundImmune checkpoint inhibitors (ICI) either alone or in combination with chemotherapy have expanded our choice of agents for the palliative treatment of non-small cell lung cancer (NSCLC) patients. Unfortunately, not all patients will experience favorable response to treatment with ICI and may even suffer from severe side effects. Therefore, prognostic and predictive markers, beyond programmed death ligand 1 (PD-L1) expression status, are of utmost importance for decision making in the palliative treatment. This review focuses on clinical, laboratory and genetic markers, most of them easily to obtain in the daily clinical practice.ResultsRecently, a number of prognostic and predictive factors in association to palliative ICI therapy have been described in NSCLC. Besides biometric parameters and clinical characteristics of the tumor, there are useful markers from routine blood sampling as well as innovative soluble genetic markers which can be determined before and during ICI treatment. Additionally, the level of evidence is noted.ConclusionsThese factors can be helpful to predict patients' outcome and tumor response to ICI. They should be implemented prospectively in ICI based clinical trials to develop reliable algorithms for palliative NSCLC treatment.

引用

页数：16

共 167 条

[1] Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status [J].

Adachi, Yuichi ;

Tamiya, Akihiro ;

Taniguchi, Yoshihiko ;

Enomoto, Takatoshi ;

Azuma, Kouji ;

Kouno, Shunichi ;

Inagaki, Yuji ;

Saijo, Nobuhiko ;

Okishio, Kyoichi ;

Atagi, Shinji .

CANCER MEDICINE, 2020, 9 (04) :1383-1391

[2] Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors [J].

Ahmed, Jibran ;

Kumar, Arun ;

Parikh, Kaushal ;

Anwar, Asad ;

Knoll, Bettina M. ;

Puccio, Carmelo ;

Chun, Hoo ;

Fanucchi, Michael ;

Lim, Seah H. .

ONCOIMMUNOLOGY, 2018, 7 (11)

[3] SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].

ALBAIN, KS ;

CROWLEY, JJ ;

LEBLANC, M ;

LIVINGSTON, RB .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626

[4]

[Anonymous], 2011, OXFORD LEVELS EVIDEN, V2

[5]

[Anonymous], 2019, ANN ONCOL

[6] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[7] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Mezquita, Laura ;

Long, Niamh ;

Rizvi, Hira ;

Auclin, Edouard ;

Ni, Andy ;

Martinez-Bernal, Gala ;

Ferrara, Roberto ;

Lai, W. Victoria ;

Hendriks, Lizza E. L. ;

Sabari, Joshua K. ;

Caramella, Caroline ;

Plodkowski, Andrew J. ;

Halpenny, Darragh ;

Chaft, Jamie E. ;

Planchard, David ;

Riely, Gregory J. ;

Besse, Benjamin ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+

[8] Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Jordan, Emmett ;

Kim, Hyunjae Ryan ;

Dienstag, Jordan ;

Yu, Helena A. ;

Sanchez-Vega, Francisco ;

Lito, Piro ;

Berger, Michael ;

Solit, David B. ;

Hellmann, Matthew ;

Kris, Mark G. ;

Rudin, Charles M. ;

Ni, Ai ;

Arcila, Maria ;

Ladanyi, Marc ;

Riely, Gregory J. .

CLINICAL CANCER RESEARCH, 2018, 24 (02) :334-340

[9] Inflammation and cancer: back to Virchow? [J].

Balkwill, F ;

Mantovani, A .

LANCET, 2001, 357 (9255) :539-545

[10] Cancer-associated cachexia [J].

Baracos, Vickie E. ;

Martin, Lisa ;

Korc, Murray ;

Guttridge, Denis C. ;

Fearon, Kenneth C. H. .

NATURE REVIEWS DISEASE PRIMERS, 2018, 4

← 1 2 3 4 5 6 7 8 9 10 →